Sol-Gel Technologies Past Earnings Performance
Past criteria checks 0/6
Sol-Gel Technologies has been growing earnings at an average annual rate of 16.9%, while the Pharmaceuticals industry saw earnings growing at 9.7% annually. Revenues have been declining at an average rate of 5.5% per year.
Key information
16.9%
Earnings growth rate
24.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | -5.5% |
| Return on equity | -70.5% |
| Net Margin | -1,752.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Sol-Gel Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2 | -27 | 7 | 0 |
| 30 Sep 23 | 1 | -28 | 8 | 0 |
| 30 Jun 23 | 1 | -26 | 8 | 0 |
| 31 Mar 23 | 5 | -20 | 8 | 0 |
| 31 Dec 22 | 4 | -15 | 7 | 0 |
| 30 Sep 22 | 25 | 5 | 7 | 0 |
| 30 Jun 22 | 33 | 10 | 7 | 0 |
| 31 Mar 22 | 31 | 2 | 8 | 0 |
| 31 Dec 21 | 31 | 3 | 8 | 0 |
| 30 Sep 21 | 13 | -17 | 10 | 0 |
| 30 Jun 21 | 6 | -27 | 11 | 0 |
| 31 Mar 21 | 6 | -26 | 11 | 0 |
| 31 Dec 20 | 9 | -29 | 11 | 0 |
| 30 Sep 20 | 11 | -29 | 10 | 0 |
| 30 Jun 20 | 13 | -28 | 10 | 0 |
| 31 Mar 20 | 20 | -26 | 9 | 0 |
| 31 Dec 19 | 23 | -25 | 8 | 0 |
| 30 Sep 19 | 19 | -30 | 7 | 28 |
| 30 Jun 19 | 14 | -30 | 6 | 0 |
| 31 Mar 19 | 6 | -32 | 6 | 34 |
| 31 Dec 18 | 0 | -32 | 6 | 0 |
| 30 Sep 18 | 0 | -26 | 5 | 22 |
| 30 Jun 18 | 0 | -32 | 6 | 16 |
| 31 Mar 18 | 0 | -32 | 7 | 25 |
| 31 Dec 17 | 0 | -32 | 6 | 0 |
| 30 Sep 17 | 0 | -31 | 6 | 25 |
| 30 Jun 17 | 0 | -24 | 4 | 20 |
| 31 Mar 17 | 0 | -22 | 3 | 19 |
| 31 Dec 16 | 0 | -21 | 4 | 17 |
| 31 Dec 15 | 0 | -10 | 2 | 7 |
Quality Earnings: 4SG is currently unprofitable.
Growing Profit Margin: 4SG is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4SG is unprofitable, but has reduced losses over the past 5 years at a rate of 16.9% per year.
Accelerating Growth: Unable to compare 4SG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4SG is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.8%).
Return on Equity
High ROE: 4SG has a negative Return on Equity (-70.48%), as it is currently unprofitable.